Refractory diffuse large ce lymphoma large b cell diffuse. Medical search. Frequent questions

Diffuse large B-cell lymphoma (DLBCL) is a cancer of B cells, a type of lymphocyte that is responsible for producing antibodies. (wikipedia.org)
Usually DLBCL arises from normal B cells, but it can also represent a malignant transformation of other types of lymphoma (particularly marginal zone lymphomas) or, in rare cases termed Richter's transformation, chronic lymphocytic leukemia. (wikipedia.org)
However, the usual treatment for most subtypes of DLBCL is chemotherapy combined with a monoclonal antibody drug that targets the disease's cancerous B-cells, usually rituximab. (wikipedia.org)
The World Health Organization, 2008, classification system defined more than a dozen subtypes, each of which was identified based on the location of the tumor, the presence of other cell types such as T cells in the tumor, and whether the patient had certain other illnesses related to DLBCL. (wikipedia.org)
Based on further research, the World Health Organization, 2016, reclassified DLBCL into its most common subtype, diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). (wikipedia.org)
DLBCL cases that do not fit the distinctive clinical presentation, tissue morphology, neoplastic cell phenotype, and/or pathogen-associated criteria of other DLBCL subtypes are termed Diffuse large B-cell lymphoma, not otherwise specified: DLBCL, NOS, while representing 80-85% of all DLBCL cases, is a diagnosis of exclusion. (wikipedia.org)
Although chimeric antigen receptor (CAR) T-cell therapy has been a life-saving treatment for some patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other hematologic malignancies, additional therapies may be able to perform equally well in select patients, according to Andrew D. Zelenetz, MD, PhD, Medical Director, Quality Informatics, Memorial Sloan Kettering Cancer Center, New York City. (theoncologynurse.com)
So far, the FDA approved 3 CAR T-cell therapies, including tisagenlecleucel (Kymriah) for relapsed or refractory B-cell precursor acute lymphoblastic leukemia and for relapsed or refractory DLBCL, axicabtagene ciloleucel (Yescarta) for relapsed or refractory DLBCL, and most recently, brexucabtagene autoleucel (Tecartus) for relapsed or refractory mantle-cell lymphoma. (theoncologynurse.com)
The approval of axicabtagene ciloleucel was based on the findings of ZUMA-1, a phase 1/2 clinical trial that included 108 patients with refractory DLBCL, primary mediastinal B-cell lymphoma, or transformed follicular lymphoma. (theoncologynurse.com)
The JULIET study included 111 patients with relapsed or refractory DLBCL who received tisagenlecleucel. (theoncologynurse.com)
Lisocabtagene maraleucel is a new CD19-directed CAR T-cell therapy that was studied in the TRANSCEND trial in patients with relapsed or refractory heavily pretreated DLBCL (Abramson JS, et al. (theoncologynurse.com)
Studies show that all 3 CAR T-cell agents represent a new treatment for relapsed or refractory DLBCL. (theoncologynurse.com)
A randomized trial is needed to compare CAR T-cell therapy to ASCT before CAR T-cell replaces transplant" in patients with relapsed or refractory DLBCL. (theoncologynurse.com)
The BLA is supported by data from the pivotal phase 1 study ( TRANSCEND NHL 001 ) that assessed the safety, antitumor activity, and pharmacokinetics of liso-cel in 268 patients with relapsed or refractory large B-cell non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), high-grade lymphoma (HGL), primary mediastinal B-cell lymphoma (PMBCL), and Grade 3B follicular lymphoma (FL). (empr.com)
In patients with DLBCL and HGBCL, the median duration of response (DOR) was 15.5 months (95% CI, 9.7-20.8), and in patients with LBCL who had prior exposure to CAR T-cell therapy, the median DOR had not yet been reached. (targetedonc.com)
Developed utilizing the DuoBody platform, epcoritamab is a CD3xCD20 bispecific antibody that received accelerated approval from the FDA in May 2023 for use in adult patients with relapsed/refractory DLBCL not otherwise specified, including DLBCL arising from indolent lymphoma, and HGBCL, following at least 2 lines of systemic treatment. (targetedonc.com)
this included 148 patients with DLBCL and HGBCL, 4 patients with PMBCL, and 5 patients with follicular lymphoma grade 3b. (targetedonc.com)
In the EPCORE NHL-3 trial, subcutaneous epcoritamab monotherapy demonstrated responses in a considerable number of patients with relapsed/refractory DLBCL, indicating that this approval is of great significance. (nxtaltfoods.com)
In the phase 1/2 EPCORE NHL-3 trial, 36 patients with relapsed or refractory DLBCL after two or more lines of treatment demonstrated similar results with an ORR of 56 percent ([95 percent CI: 38.1-72.1]) and a CR rate of 44 percent (data cutoff: January 31, 2022). (nxtaltfoods.com)
Gene expression studies have confirmed that PMBCL is molecularly different from DLBCL and that it may resemble Hodgkin lymphoma. (medscape.com)
Gene expression profiling has clearly demonstrated that this disease entity is different from diffuse large B-cell lymphoma (DLBCL) and has identified several deregulated pathways involved in the pathogenesis of PMBCL. (medscape.com)
Last Friday, the FDA approved tafasitamab to be used in combination with lenalidomide for second-line treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL, meeting the needs of patients who are not eligible for an autologous stem cell transplant. (ajmc.com)
The US Food and Drug Administration (FDA) has approved Polivy (polatuzumab vedotin-piiq) for use in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) to treat adults who have previously untreated diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. (cancertherapyadvisor.com)
Polatuzumab vedotin now has regular approval for use in combination with bendamustine and rituximab to treat patients with relapsed or refractory DLBCL who have received at least 2 prior therapies. (cancertherapyadvisor.com)
Epcoritamab-bysp (Epkinly - Genmab), a bispecific CD20-directed CD3 T-cell engager, has received accelerated approval from the FDA for subcutaneous treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise. (medicalletter.org)
Tazemetostat was studied in an open-label multicenter study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) who received tazemetostat 800 mg twice daily. (targetedonc.com)
One patient with diffuse large B-cell lymphoma (DLBCL) experienced a CR and finished 5 cycles of treatment, while another patient with the same disease achieved a PR and completed 3 cycles. (oncnursingnews.com)
To be eligible for the dose-escalation portion of the study, patients needed to be 18 years of age or older with either advanced unresectable solid tumors (n = 67) or relapsed/refractory DLBCL (n = 2). (oncnursingnews.com)
Two cohorts of patients received the 45-mg dose of CC-90010: cohort 1 was comprised of 14 patients with relapsed/refractory DLBCL and cohort 2 was comprised of 1 patient with advanced basal cell carcinoma and 1 patient with NUT midline carcinomas. (oncnursingnews.com)
The recently-opened third cohort is comprised of patients with relapsed/refractory DLBCL who are receiving the agent at the 30-mg dose. (oncnursingnews.com)
High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL. (viictr.org)
See the complete profile on LinkedIn and discover Lei's connections and Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. (netlify.app)
Chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel, sold as Yescarta, was authorized earlier this week by the European Commission (EC) as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) after 2 or more lines of systemic therapy. (cgtlive.com)

So clearly, the treatment of relapsed or refractory follicular lymphoma is in evolution. (reachmd.com)
This is the first FDA-approved bispecific antibody in the treatment of B-cell lymphomas, and it was approved on the basis of a conducted single-agent study, which evaluated mosunetuzumab monotherapy in patients with relapsed or refractory follicular lymphoma in the third line and beyond. (reachmd.com)

It is the most common form of non-Hodgkin lymphoma among adults, with an annual incidence of 7-8 cases per 100,000 people per year in the US and UK. (wikipedia.org)
Understand recently presented clinical trial results informing the selection of available therapeutic agents in the nonresearch care of patients with newly diagnosed and relapsed/refractory Hodgkin lymphoma. (researchtopractice.com)
Primary mediastinal B-cell lymphoma (PMBCL) is relatively rare B-cell non-Hodgkin lymphoma that comprises 6-12% of all diffuse large B-cell lymphomas (DLBCLs) and 2-4% of all non-Hodgkin lymphomas. (medscape.com)
The weak CD30 expression can aid in differentiating PMBCL from anaplastic large cell lymphoma and classic Hodgkin lymphoma. (medscape.com)
Non-Hodgkin lymphoma (NHL) is the seventh most common cancer in the United States, with approximately 77,000 new cases and 20,000 deaths in 2020. (cancernetwork.com)
The reversible BET inhibitor CC-90010 was found to have preliminary antitumor activity in patients with heavily pretreated, advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma. (oncnursingnews.com)
The reversible BET inhibitor CC-90010 was found to have preliminary antitumor activity in patients with heavily pretreated, advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma, according to the updated results of a phase 1 study (NCT03220347) presented during the 2020 ESMO Virtual Congress. (oncnursingnews.com)
Whereas Hodgkin lymphoma rarely causes ocular disease, non-Hodgkin lymphoma (NHL) is the most common type of ocular lymphoma. (medscape.com)
Treatment protocols for classical Hodgkin lymphoma (HL) are provided below, including treatment for early-stage, advanced-stage, and relapsed/refractory disease. (medscape.com)
The Marketing Authorization Application (MAA) was approved based on data from the ZUMA-1 trial that investigated axicabtagene ciloleucel in adult patents with refractory aggressive non-Hodgkin lymphoma. (cgtlive.com)
Extranodal NK/T cell lymphoma is a rare non-Hodgkin lymphoma mainly involving the upper aerodigestive tract, even rarer is primary extranasal disease involving the intestine. (frontiersin.org)
Extranodal NK/T cell lymphoma nasal type (ENKTL) is a subtype of non-Hodgkin lymphoma (NHL). (frontiersin.org)

P. Connor Johnson, MD, and Jeremy S. Abramson MD, MMSc, discuss available treatments for patients with Burkitt lymphoma and high-grade B-cell lymphoma. (cancernetwork.com)
This article reviews the current data and future directions in the management of Burkitt lymphoma (BL) and high-grade B-cell lymphoma (HGBL). (cancernetwork.com)
1 A significant minority of these cases were the especially aggressive B-cell lymphomas Burkitt lymphoma (BL) and high-grade B-cell lymphoma (HGBL), the latter of which includes the histologic subtypes HGBL with MYC and BCL2 and/or BCL6 translocations (conventionally referred to as double-hit lymphoma [DHL]) and HGBL, not otherwise specified (NOS). (cancernetwork.com)
The agent was found to lead to tumor reduction when evaluated in xenograft models and encouraging activity in patients with advanced malignancies.2 Because BET proteins are key players in the regulation of MYC oncogene expression, investigators hypothesized that CC-90010 may represent a potential effective option for patients with high-grade B-cell lymphoma, particularly those who have MYC rearrangements. (oncnursingnews.com)

Malignant causes included primary or secondary cardiac tumors, lung cancer, mediastinal tumors, or lymphoma, which may obstruct or compress the superior vena cava. (frontiersin.org)
Example of mediastinal lymphoma at diagnosis. (medscape.com)
Flow cytometry studies identify a unique immunophenotype profile for primary mediastinal B-cell lymphoma (PMBCL). (medscape.com)
Several studies have explored the underlying genetic and molecular features that lead to the evolution of primary mediastinal B-cell lymphoma (PMBCL). (medscape.com)

Brentuximab vedotin (trade name: Adcetris, marketed by Seattle Genetics and Millennium/Takeda) [11] was approved for relapsed HL and relapsed systemic anaplastic large-cell lymphoma (sALCL)) by the FDA on August 19, 2011 and received conditional marketing authorization from the European Medicines Agency in October 2012. (wikipedia.org)
Orbital and adnexal lymphoma is associated with systemic lymphoma in 30-35% of cases. (medscape.com)
Hence, all patients with ocular lymphoma should have a complete workup to rule out systemic lymphoma. (medscape.com)
The drug has been registered for clinical use for two indications, namely patients up to 25 years of age with B-cell acute lymphoblastic leukaemia that is refractory, in relapse post-transplant or in second or later relapse, or adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. (ladyexpat.com)

Some people worry about using a CD19 antibody in patients for whom you're considering trying to get them to CAR [chimeric antigen receptor] T cells. (onclive.com)
But we have to remember that prior to the introduction of CAR [chimeric antigen receptor] T-cell therapy, all these patients would die. (onclive.com)
If it's so great a therapy in patients who have relapsed after an autologous transplant or are refractory-ineligible-they never make it to a transplant-why are we transplanting people? (onclive.com)
Download these slides on therapeutic approaches to managing patients with relapsed/refractory diffuse large B-cell lymphoma. (practicingclinicians.com)
CAR T-cell therapy can be lifesaving for some patients, but because CAR T-cells are genetically engineered through a laborious process, the treatment is very expensive. (theoncologynurse.com)
Some patients achieve partial response from high-dose chemotherapy and stem-cell transplant. (theoncologynurse.com)
12 months) chemotherapy evaluated the outcomes of patients who were positron emission tomography (PET)-positive and had a partial response after second-line chemotherapy before they underwent autologous hematopoietic stem-cell transplant (ASCT). (theoncologynurse.com)
For chemosensitive patients, it's not clear that CAR T-cell is superior to high-dose chemotherapy and stem-cell transplant if the patient is PET-positive after chemotherapy. (theoncologynurse.com)
however, Kymriah holds an additional indication to treat B-cell precursor acute lymphoblastic leukemia in certain pediatric and young adult patients. (pharmacytimes.com)
While more than half of patients with AML go into remission after treatment with chemotherapy, many relapse due to residual leukemia cells evading both chemotherapy and the immune system. (pharmacytimes.com)
CYAD-01 genetically modifies the patients' immune cells to express a natural killer receptor that targets leukemia cells. (pharmacytimes.com)
Bristol-Myers Squibb) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after at least 2 prior therapies. (empr.com)
In the phase 1/2 EPCORE NHL-1 trial (NCT03625037), treatment with subcutaneous epcoritamab-bysp (Epkinly) achieved deep and durable responses in patients with relapsed or refractory large B-cell lymphoma (LBCL). (targetedonc.com)
Subcutaneous epcoritamab is a bispecific antibody with high single-agent activity in patients with relapsed or refractory LBCL. (targetedonc.com)
The trial enrolled patients with relapsed or refractory, CD20-positive mature B-cell neoplasms who previously received 2 or more lines of antineoplastic therapy, including at least 1 anti-CD20 monoclonal antibody.1 Patients were required to have measurable disease by PET/CT and an ECOG performance status of 0 to 2. (targetedonc.com)
Notably, 70% of patients had received 3 or more lines of therapy, 61% had primary refractory disease, 83% were refractory to their last therapy, and 75% were refractory to at least 2 consecutive lines of treatment. (targetedonc.com)
Recall new data with agents and strategies currently under investigation for various lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients. (researchtopractice.com)
Despite recent advances in the treatment of LBCL, the prognosis for patients with relapsed/refractory LBCL remains generally poor, and there is a need for additional treatment options for patients whose condition has worsened after multiple lines of treatment," said Koji Izutsu, MD, PhD, principal investigator of the phase 1/2 EPCORE NHL-3 trial in Japan and Head of the Hematology Department, National Cancer Center Hospital. (nxtaltfoods.com)
In the phase 1/2 EPCORE NHL-1 trial, 157 patients with relapsed or refractory LBCL demonstrated an overall response rate (ORR) of 63 percent ([95 percent confidence interval (CI): 55.0-70.6]) and a complete response (CR) rate of 39 percent (data cutoff: January 31, 2022). (nxtaltfoods.com)
This approval marks an important milestone for patients in Japan with relapsed/refractory large B-cell lymphoma who are in need of alternative therapeutic options and who may now have access to EPKINLY, the first approved T-cell engaging bispecific antibody," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. (nxtaltfoods.com)
We are working closely with AbbVie to deliver EPKINLY to patients in Japan as quickly as possible and we remain committed to continue evaluating epcoritamab as a potential core therapy across B-cell malignancies. (nxtaltfoods.com)
This is critical, as Reed-Sternberg-like cells can be present in patients with PMBCL. (medscape.com)
Her clinical and research interests lie in improving the outcomes of patients with lymphoma. (mdanderson.org)
Dr. Pinnix's ultimate aspiration is to advance the clinical outcomes of patients afflicted with Hodgkin's and Non-Hodgkin's lymphoma via the minimization of normal tissue toxicity related to radiotherapy. (mdanderson.org)
But it's really clearly a very promising direction for our field, that we see the development of off-the-shelf T-cell-engaging therapies that we can offer our patients. (reachmd.com)
This approval was because this agent showed very high efficacy in patients with relapsed/refractory follicular lymphoma, including high overall response rates and complete response rates. (reachmd.com)
When looking at the ability for patients to receive this agent, it's an off-the-shelf agent, so it's easier for many patients to access than some of the other therapies like CAR T-cell therapy. (reachmd.com)
[ 10 ] Intraocular lymphoma typically affects elderly patients, with reported series having mean ages in the seventh decade of life. (medscape.com)
From Active to Non-active Giant Cell Arteritis: Longitudinal Monitoring of Patients on Glucocorticoid Therapy in Combination With Leflunomide. (tugraz.at)
Although 5-year survival rates in the first-line setting range from 60% to 70%, up to 50% of patients become refractory to or relapse after treatment. (netlify.app)
The developer of Yescarta, Kite Pharma, a subsidiary of Gilead, said in a statement that it was in "ongoing discussions with NICE to identify appropriate treatment comparators which can clarify how cell therapy may be made available to patients in the UK. (cgtlive.com)
Gühne F , Seifert P , Theis B , Steinert M , Freesmeyer M , Drescher R . PSMA-PET/CT in Patients with Recurrent Clear Cell Renal Cell Carcinoma: Histopathological Correlations of Imaging Findings. (mitteldeutsches-krebszentrum.de)

CAR-expression on T or NK cells allows them to specifically target cancer cells via recognition of tumor associated antigens. (nature.com)
Binding of a tumor antigen via the scFv activates the T cell in a major histocompatibility-independent manner which leads to a cytotoxic response [ 3 ]. (nature.com)
The addition of separate adapter molecules (AMs) specific for tumor antigens and CAR-immune cells targeting these AMs allows a more precise and temporally limited therapy. (nature.com)
Baseline transesophageal echocardiography with 3D reconstruction, showing a large tumor arising from the lateral wall of the right atrium (white arrows). (frontiersin.org)
A large tumor mass is present in the anterior mediastinum, and an associated pleural effusion can also be seen. (medscape.com)
The tumor cells resemble immunoblasts or centroblasts, and, in many cases, sclerosis and fibrosis can be identified. (medscape.com)
[1] Unlike chemotherapy , ADCs are intended to target and kill tumor cells while sparing healthy cells. (wikipedia.org)
An anticancer drug is coupled to an antibody that targets a specific tumor antigen (or protein ) that, ideally, is only found in or on tumor cells. (wikipedia.org)
The biochemical reaction that occurs upon attaching triggers a signal in the tumor cell, which then absorbs, or internalizes, the antibody together with the linked cytotoxin. (wikipedia.org)
2 EZH2 has also been implicated in tumor initiation and progression, migration, angiogenesis, stem cell self-renewal, and activated T-regulatory cell functioning. (targetedonc.com)
The underlying mechanism of action of CDBPA in Burkitt`s lymphoma was tested in vitro and its effect on tumor size and survival was tested in a NOD-scid mice model. (longdom.org)
Burkitt's Lymphoma (BL) is a rare, aggressive and fast growing human tumor and was the first human tumor to be associated with an Epstein-Barr Virus (EBV) [ 1 ]. (longdom.org)

From the archives of MD Anderson Cancer Center: Sporadic Burkitt lymphoma with a complex karyotype and SOX11 expression. (viictr.org)
CDBPA, possesses strong in vitro and in vivo activity against Ramos cells, representing a potential approach for therapy of Burkitt lymphoma. (longdom.org)

Double-hit lymphoma (DHL) represents HGBL with translocations of the oncogene MYC along with either BCL2 or BCL6, or both. (cancernetwork.com)
HGBL, not otherwise specified (NOS) is a heterogeneous, aggressive, mature B-cell lymphoma that does not meet criteria for BL, DHL, or diffuse large B-cell lymphoma NOS. (cancernetwork.com)
The aggressive B-cell lymphomas BL, DHL, and HGBL, NOS are unique diseases with specific pathogenesis and biology. (cancernetwork.com)

According to the case study, an acute myeloid leukemia patient has remained cancer free for 9 months following treatment with the chimeric antigen receptor (CAR) T-cell treatment, CYAD-01, and a bone marrow transplant. (pharmacytimes.com)
Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools for combating hematological diseases confronted with pressing medical needs. (nature.com)
One way to achieve this is to genetically modify immune cells, mainly T cells and recently also natural killer (NK) cells, to express chimeric antigen receptors (CARs). (nature.com)
Liso-cel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy with a defined composition of CD8+ and CD4+ CAR T cells. (empr.com)
The Department of Health today said the Pharmacy & Poisons Board of Hong Kong earlier issued a licence to authorise a local company to manufacture autologous chimeric antigen receptor T cells, ie CAR-T cells, for clinical trial, but not for clinical treatment. (ladyexpat.com)

Another interest lies in the identification of improved treatment strategies that incorporate radiation in the management of aggressive and refractory lymphomas. (mdanderson.org)

The European Commission approved Inotuzumab ozogamicin [14] as a monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) on June 30, 2017 under the trade name Besponsa® (Pfizer/Wyeth), [15] followed on August 17, 2017 by the FDA. (wikipedia.org)
Acute myeloid leukemia (AML) is a malignant disorder of the hematopoietic stem cells characterized by abnormal proliferation of myeloid blast cells in the bone marrow and blood, preventing them from further differentiating into the specialized cells of the bone marrow and thus causing pancytopenia. (dovepress.com)
Resveratrol-induced apoptosis is enhanced in acute lymphoblastic leukemia cells by modulation of the mitochondrial permeability transition pore. (nature.com)
Yescarta carries a US price tag of $373,000, and tisagenlecleucel, (sold as Kymriah for the treatment of pediatric and adult B-cell acute lymphoblastic leukemia) comes at the hefty price of $475,000 for a one-time dose. (cgtlive.com)

Interim phase II tazemetostat safety data were presented at the 14th International Conference on Malignant Lymphoma in June 2017. (targetedonc.com)
The incidence of lymphoproliferative ocular diseases, especially malignant lymphoma, has increased over the years. (medscape.com)

I suspect we'll have tafasitamab prior to CD19-directed CAR T-cell therapy, and vice versa. (onclive.com)
As John mentioned, in the small amount of data that currently exist, it does not appear that introducing tafasitamab prior to CD19-directed CAR T-cell therapy is going to impact that legacy. (onclive.com)
The 2 of you remarked on all the obstacles associated with putting a patient on CAR T-cell therapy. (onclive.com)
Maybe we should just be going directly to CAR T-cell therapy. (onclive.com)
And so at the same time we need to broaden the scope of the availability of CAR T-cell therapy. (onclive.com)
Do you have to have active disease, Kami, to get CAR T-cell therapy? (onclive.com)
But I collected the CAR T cells, gave them bridging therapy, and all the disease went away. (onclive.com)
Furthermore, CAR T-cell therapy is associated with serious adverse events, including cytokine release syndrome (CRS) and neurologic toxicities. (theoncologynurse.com)
A fourth CAR T-cell therapy, lisocabtagene maraleucel, has recently been submitted for FDA approval for relapsed or refractory large B-cell lymphoma. (theoncologynurse.com)
Twenty-six percent were primary refractory, and 53% were refractory to 2 prior lines of therapy. (theoncologynurse.com)
The thinking now is that if the patient is not in complete response, you can go on to CAR T-cell therapy," Dr Zelenetz noted. (theoncologynurse.com)
The progression-free survival and overall survival plateau was approximately 45%, which was similar to the outcomes achieved with third-line CAR T-cell therapy. (theoncologynurse.com)
Lately, CAR-NK cell therapies have also come into focus as novel therapeutic options to address hurdles related to CAR-T cell therapies, such as therapy-induced side effects. (nature.com)
Most CAR-T cell-based gene therapy products that are under clinical evaluation consist of autologous enriched T cells, whereas CAR-NK cell-based approaches can be generated from allogeneic donors. (nature.com)
Besides modification based on a second-generation CAR, more advanced CAR-immune cell therapeutics are being tested, which utilize precise insertion of genes to circumvent graft-versus-host disease (GvHD) or employ a dual targeting approach and adapter CARs in order to avoid therapy resistance caused by antigen loss. (nature.com)
An autologous CAR-T or NK cell therapy comprises several steps as shown in Fig. 1 . (nature.com)
Following positive results from the phase 1/2 EPCORE NHL-1 trial, epcoritamab is currently under evaluation across different lines of therapy and in various combinations for diffuse large B-cell lymphoma. (targetedonc.com)
Those who had prior exposure to CAR T-cell therapy were permitted. (targetedonc.com)
Certainly, in comparison to CAR T-cell therapy, this too being a T-cell-engaging treatment, really has much lower rates of the significant toxicities associated with T-cell-engaging treatments. (reachmd.com)
Involved-site radiation therapy (ISRT) is typically recommended, because high-dose, large-field radiation therapy (LFRT) increases risk for heart disease, pulmonary dysfunction, and secondary cancers. (medscape.com)
On the treatment side, the Hospital Authority pointed out that it began its CAR-T cell therapy pilot programme at Queen Mary Hospital in 2021, adding that the service has been extended to Hong Kong Children's Hospital and Prince of Wales Hospital. (ladyexpat.com)
It is now prescribing Tisagenlecleucel for CAR-T cell therapy. (ladyexpat.com)
Currently, Tisagenlecleucel is the only CAR-T cell therapy drug registered in Hong Kong for clinical use, and it is not manufactured by the pharmaceutical product manufacturer licensed on August 30, the authority noted. (ladyexpat.com)
Kymriah was the first CAR T-cell therapy approved in August 2017, and Yescarta followed shortly thereafter in October 2017 . (cgtlive.com)

Imaging work-up revealed an obstructing right atrial mass, which was subsequently excised and diagnosed as primary cardiac lymphoma. (frontiersin.org)
This confirmed the diagnosis of primary cardiac lymphoma (PCL). (frontiersin.org)
Compounds derived from PS127 significantly upregulated production of reactive oxygen species (ROS) in AML cells and triggered ferroptotic, necroptotic, and/or apoptotic cell death in AML cell lines and refractory/relapsed AML primary samples. (nature.com)
Fig. 5: PS compounds induced synergistic cytotoxicity when combined with other anti-cancer drugs in AML cell lines and primary AML samples. (nature.com)
Fig. 6: Flow cytometry evaluation of viable cell number and apoptosis induction in primary AML samples and healthy bone marrow cells. (nature.com)
It may be either a primary intraocular lymphoma (PIOL) or a secondary intraocular lymphoma (SIOL). (medscape.com)
PIOL is mainly a subtype of primary CNS lymphoma (PCNSL). (medscape.com)
We present a case of primary intestinal NK/T cell lymphoma with diagnostic challenge, which eventually developed into multiple intestinal perforations. (frontiersin.org)
Early diagnosis of primary intestinal NK/T cell lymphoma is frequently difficult. (frontiersin.org)
Incidence of primary large bowel lymphomas comprises only 0.2-0.6% of large bowel malignant tumors ( 3 ). (frontiersin.org)

This includes transformed follicular lymphoma and transformed marginal-zone lymphoma. (theoncologynurse.com)

We're taking a closer look at the rationale and evidence for using bispecific antibodies in follicular lymphoma. (reachmd.com)
So the bispecific antibodies, or T-cell engagers - the current ones that target CD20 on the B-cell by CD3 on the T-cell - have shown a lot of promise in relapsed/refractory follicular lymphoma. (reachmd.com)
Odronextamab is a bispecific antibody to treat relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. (formularywatch.com)

Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of diffuse large B-cell lymphoma to determine the current and/or potential utility of each in clinical practice. (researchtopractice.com)
Consider current research findings and clinical and biologic factors in the up-front and subsequent treatment of mantle cell lymphoma. (researchtopractice.com)
So, this is a promising agent that has been added to our treatment for relapsed/refractory follicular lymphoma, and we look to the future, where we have potentially even more bispecifics available in this setting. (reachmd.com)
During treatment, 1 patient (1.4%) with diffuse astrocytoma achieved a complete response (CR) and continued on the treatment for 18 cycles until before experiencing disease progression. (oncnursingnews.com)
The prognosis for ocular lymphoma depends on the tumor's histologic type and stage and the treatment employed. (medscape.com)
For treatment of Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma. (aetna.com)
It stressed that the licence specified that the company is authorised to manufacture CAR-T cells only for the purpose of clinical trials instead of any clinical treatment purpose. (ladyexpat.com)
If the company wishes to manufacture CAR-T cells for clinical treatment purposes, it must first apply to the board to alter the licensing conditions. (ladyexpat.com)
The department said manufacturers of any CAR-T cells for treatment purposes should apply to the board for registration in accordance with the regulations, adding that the board will only approve the application if the product meets safety, efficacy and quality criteria. (ladyexpat.com)
It stressed that using CAR-T cells for clinical trials or treatment purposes without approval is illegal and may be considered as a criminal offence. (ladyexpat.com)
Only 1 day after the European Commission approved CAR T-cell therapies, the National Institute for Health and Care Excellence deemed the treatment too expensive to justify on Britain's state-funded health service. (cgtlive.com)
Gene expression experiments indicated that CARD9, BNIP3(L), TNFRSF-1B, and TNFRSF-25 genes are highly expressed in Ramos BL cells following treatment with CDBPA. (longdom.org)

First approvals for BRUKINSA in China and its first indication for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. (e-cancer.fr)

This type of lymphoma represents 1% of NHLs, 1% of intracranial tumors, and less than 1% of intraocular tumors. (medscape.com)

Further, inhibiting I-kappa-B, which activates NF-kappa-B signaling, was shown to induce cell kill in vitro in PMBCL cell-lines. (medscape.com)

HIV), and the Helicobacter pylori bacterium are also associated with the development of certain subtypes of diffuse large B-cell lymphoma. (wikipedia.org)
Diffuse large B-cell lymphoma encompasses a biologically and clinically diverse set of disease subtypes, many of which are difficult to separate from one another based on well-defined and widely accepted criteria. (wikipedia.org)

Bone marrow examination showed the proliferation of hematopoietic cells were active, mainly granulocytes, and immature granulocytes increased. (frontiersin.org)

In this review, we are going to take a closer look at the commercial CAR-T cell therapies, as well as on CAR-T and CAR-NK cell products, which are currently under evaluation in clinical trials, that are being conducted in Germany. (nature.com)
There are currently 2 CAR T-cell therapies available on the market, and although both treatments have many benefits, they come at a steep price. (cgtlive.com)

Currently, more than 500 CAR-T and 17 CAR-NK cell trials are being conducted worldwide including the four CAR-T cell products Kymriah, Yescarta, Tecartus and Breyanzi, which are already available on the market. (nature.com)

CDBPA exerted a strong apoptotic cell death. (longdom.org)

The incidence of ocular lymphoma increases with advancing age. (medscape.com)

Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical andbiologic heterogeneity. (medicalletter.org)
The statement said the board issued a licence for a manufacturer on August 30 according to the Pharmacy & Poisons Regulations, authorising the company to manufacture CAR-T cells for clinical trials. (ladyexpat.com)
Ma DD , 2007 , 'Expression of Neurofilament Proteins in Adult Bone Marrow Mesenchymal Stem Cells and Embryonic Stem Cells and Their Clinical Potential' , in Davenport LP (ed. (edu.au)

it accounts for 1% to 2% lymphoma in adults and up to 40% of lymphoma in the U.S. and Western Europe [ 5 ]. (longdom.org)

Normally, potentially malignant cells are continuously eliminated by the immune system, but cancer cells can accumulate certain mutations, which allow them to escape these mechanisms [ 2 ]. (nature.com)
Cancer immunotherapies aim to support or boost the patient's immune system to enable the effective clearance of cancer cells. (nature.com)
A variety of cancer types exhibit chromatin-modifying mutations, which often correlate with cell fate decisions. (targetedonc.com)
As in normal stem cells, EZH2 is highly expressed in cancer stem cell populations and suppresses differentiation via repression of lineage-specific factors to maintain these populations. (targetedonc.com)
Fig. 2: Mitochondria-related mechanistic effects of PS hit compounds on cancer and normal blood cells. (nature.com)
Inflammation and metabolism in cancer cell-mitochondria key player. (nature.com)
Over the years, different systems have been used to classify lymphomas, including the Rappaport Classification (used until the 1970s), the Working Formulation, the National Cancer Institute Working Formulation, and the Revised European-American Lymphoma Classification (REAL). (medscape.com)
Ce bulletin signale des articles du web anglophone portant sur les divers champs d'intervention de l'Institut national du cancer. (e-cancer.fr)
Professor Ma heads the Blood, Stem Cell and Cancer Research Programme at St Vincent's Centre for Applied Medical Research, Sydney. (edu.au)
Background and study aims Endoscopic submucosal dissection (ESD) is one of the most minimally invasive treatments for superficial squamous cell cancer of the pharynx. (bvsalud.org)

Appreciate how emerging research data affect the best-practice management of peripheral T-cell lymphoma. (researchtopractice.com)
Structure-activity relationship studies identified six analogs from two original scaffolds that had over an order of magnitude difference between LD50 in AML and healthy peripheral blood mononuclear cells. (nature.com)
Histopathology of peripheral nerve and sympathetic ganglion from a patient with autonomic failure, oat-cell carcinoma of the lung, and positive anti-HU antibody titer. (medscape.com)

Immunohistochemistry staining tested positive for CD20 ( Figure 4 ), leading to a diagnosis of right atrial diffuse large B cell lymphoma, non-germinal center (activated) type. (frontiersin.org)
The surgical samples underwent pathological analysis, and a diagnosis of extranodal NK/T cell lymphoma nasal type was confirmed. (frontiersin.org)

These long-term remissions raise the possibility, but do not prove that CAR T cells could be curative for some B-cell lymphomas, including diffuse large B-cell lymphoma, low-grade lymphomas, and CLL," first author Kathryn Cappell, MD, PhD, told Oncology Times. (e-cancer.fr)

This examination showed a diffuse proliferation of large atypical lymphocytes exhibiting mitotic activity and apoptosis along with extensive areas of necrosis. (frontiersin.org)
A ) (H&E × 400): Microscopy shows a diffuse proliferation of large atypical cells. (frontiersin.org)
The retinoblastoma-E2F pathway, which regulates the cell cycle, has been demonstrated to be upstream of EZH2, which is required for proliferative gene expression and E2F-driven proliferation. (targetedonc.com)

Classical " CARs consist of an extracellular binding domain mostly derived from a monoclonal antibody fragment (single-chain variable fragment-scFv), which is linked to intracellular binding domains of the T-cell receptor complex. (nature.com)

Antibodies attach themselves to the antigens on the surface of cancerous cells. (wikipedia.org)

Arthritis can also occur, and typically affects large joints, but is rarely deforming. (medscape.com)

Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features. (viictr.org)

Stem Cell Research Advances , edn. (edu.au)

This raises the question of whether you have to go on to CAR T-cell, or can you continue with high-dose chemotherapy and stem-cell transplant," Dr Zelenetz said. (theoncologynurse.com)

Pilot in vivo efficacy studies indicate anti-leukemic efficacy in a MOLM14/GFP/LUC xenograft model, including extended survival in mice injected with leukemic cells pre-treated with PS127B or PS127E and in mice treated with PS127E at a dose of 5 mg/kg. (nature.com)

5-7 Morphologically, BL involves monomorphic medium-sized B cells with basophilic cytoplasm, numerous mitotic figures, rounded nuclei with finely clumped chromatin, myriad apoptosis, and tingible body macrophages, which result in a classic "starry sky" pattern. (cancernetwork.com)
The pharmacological NFkappaB inhibitors BAY117082 and MG132 induce cell arrest and apoptosis in leukemia cells through ROS-mitochondria pathway activation. (nature.com)
BL cells and normal fibroblasts were exposed to CDBPA for cytotoxicity screening by XTT assay, followed by cell cycle arrest, determination of apoptosis using Flow Cytometry and by annexin V/FITC/PI assay. (longdom.org)
We demonstrated that CDBPA significantly reduced cell viability and induced apoptosis via the extrinsic and the intrinsic apoptotic pathways of Burkitts lymphoma cells without causing cell cycle arrest but reduction of the various phases. (longdom.org)

Depending on the site of involvement, ocular lymphoma can be intraocular, and adnexal. (medscape.com)

Anatomy15

Organisms5

Diseases29

Chemicals and Drugs42

Analytical, Diagnostic and Therapeutic Techniques and Equipment28

Phenomena and Processes25

Disciplines and Occupations1

Information Science4

Health Care8

DLBCL33

Relapsed or refractory follicular lymphoma2

Hodgkin12

High-grade B-cell lym4

Mediastinal4

Systemic4

Patients32

Tumor12

Burkitt2

HGBL3

Chimeric antigen5

Aggressive1

Acute4

Malignant Lymphoma2

Therapy24

Primary10

Marginal zone1

Bispecific3

Treatment12

Chronic lymphocy1

Tumors1

PMBCL1

Subtypes2

Hematopoietic1

Therapies2

Kymriah1

Apoptotic cell1

Incidence1

Clinical3

Adults1

Cancer10

Peripheral3

Diagnosis2

Oncology1

Proliferation3

Receptor1

Antigens1

Affects1

Mantle1

Advances1

Stem-cell trans1

Efficacy1

Apoptosis4

Ocular1